CD33 and acute myeloid leukemia: GO, Mylotarg, GO Resistance, CD33, Gemtuzumab Toxicity, Gemtuzumab Leukemia, and Acute Myeloid Leukemia were the keywords and subject headings investigated in all the investigations.